Christopher Ritchie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christopher Ritchie has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Lingyin Li
Department of Biochemistry, Stanford University; Stanford, CA 94305, USA
3 shared publications - Anthony F. Cordova
ChEM-H Institute, Stanford University, Stanford, CA 94301
2 shared publications Rachel E. Mardjuki
Stanford University
2 shared publicationsVolker Böhnert
Stanford University
2 shared publications- Gaelen T. Hess
Stanford University
1 shared publication - Jacqueline A. Carozza
Stanford University
1 shared publication
Latest Publications
- Open Access
Human SLC46A2 is the dominant cGAMP importer in extracellular cGAMP-sensing macrophages and monocytes
Administration of exogenous CDNs to activate the cGAMP-STING pathway is a promising therapeutic strategy to unleash the full potential of cancer immunotherapy. This strategy mirrors the role of endogenous extracellular cGAMP, which we recently described as an immunotransmitter exported by cancer cells and imported into local responder cells of unknown identities to promote anti-tumoral immunity, with irradiation enhancing this effect. Here, in low-dose irradiated murine tumors, we identified CD4+ T cells, M1 macrophages, and NKG2DLow NK cells as cGAMP responder cells that have decreased STING activation upon depletion of extracellular cGAMP. At higher doses of radiation, extracellular cGAMP promoted the death of T cells and macrophages. Furthermore, we identified the orphan protein SLC46A2 as the dominant importer of cGAMP and select bacterial CDNs in human macrophages and monocytes. Together, we provide the first cellular and molecular mechanisms of cGAMP as an immunotransmitter, paving the way for effective STING pathway therapeutics.
Open AccessHuman SLC46A2 is the dominant cGAMP importer in extracellular cGAMP-sensing macrophages and monocytes
Administration of exogenous CDNs to activate the cGAMP-STING pathway is a promising therapeutic strategy to unleash the full potential of cancer immunotherapy. This strategy mirrors the role of endogenous extracellular cGAMP, which we recently described as an immunotransmitter exported by cancer cells and imported into local responder cells of unknown identities to promote anti-tumoral immunity, with irradiation enhancing this effect. Here, in low-dose irradiated murine tumors, we identified CD4+ T cells, M1 macrophages, and NKG2DLow NK cells as cGAMP responder cells that have decreased STING activation upon depletion of extracellular cGAMP. At higher doses of radiation, extracellular cGAMP promoted the death of T cells and macrophages. Furthermore, we identified the orphan protein SLC46A2 as the dominant importer of cGAMP and select bacterial CDNs in human macrophages and monocytes. Together, we provide the first cellular and molecular mechanisms of cGAMP as an immunotransmitter, paving the way for effective STING pathway therapeutics.
- Open Access
The LRRC8A:C Heteromeric Channel Is a cGAMP Transporter and the Dominant cGAMP Importer in Human Vasculature Cells
SUMMARY: Extracellular 2’3’-cyclic-GMP-AMP (cGAMP) is an immunotransmitter secreted by cancer cells and taken up by host cells to activate the anti-cancer STING pathway. No cGAMP exporter has been identified, and SLC19A1, a recently identified cGAMP importer, does not account for the import activity in most cell types. Here, we identify the LRRC8A:C heteromeric channel, a volume-regulated anion channel (VRAC), as a cGAMP transporter. This channel mediates cGAMP import or export depending on the cGAMP chemical gradient, and channel activation or inhibition modulates cGAMP transport. Other 2’3’-cyclic dinucleotides are also transported by LRRC8A:C channels, including the investigational cancer therapeutic ADU-S100. Furthermore, we demonstrate that the LRRC8A-containing channel is the dominant cGAMP importer in primary human vasculature cells. Given tumor vasculature’s regulation of immune infiltration and its disruption in response to STING agonists, we have uncovered a leading molecular mechanism for extracellular cGAMP signaling in this important anti-cancer target.
Open AccessThe LRRC8A:C Heteromeric Channel Is a cGAMP Transporter and the Dominant cGAMP Importer in Human Vasculature Cells
SUMMARY: Extracellular 2’3’-cyclic-GMP-AMP (cGAMP) is an immunotransmitter secreted by cancer cells and taken up by host cells to activate the anti-cancer STING pathway. No cGAMP exporter has been identified, and SLC19A1, a recently identified cGAMP importer, does not account for the import activity in most cell types. Here, we identify the LRRC8A:C heteromeric channel, a volume-regulated anion channel (VRAC), as a cGAMP transporter. This channel mediates cGAMP import or export depending on the cGAMP chemical gradient, and channel activation or inhibition modulates cGAMP transport. Other 2’3’-cyclic dinucleotides are also transported by LRRC8A:C channels, including the investigational cancer therapeutic ADU-S100. Furthermore, we demonstrate that the LRRC8A-containing channel is the dominant cGAMP importer in primary human vasculature cells. Given tumor vasculature’s regulation of immune infiltration and its disruption in response to STING agonists, we have uncovered a leading molecular mechanism for extracellular cGAMP signaling in this important anti-cancer target.
- Open Access
In response to Luteijn et al .: Concerns regarding cGAMP uptake assay and evidence that SLC19A1 is not the major cGAMP importer in human PBMCs
We previously reported that SLC19A1 is an importer of the immunotransmitter 2’3’-cyclic-GMP-AMP (cGAMP) 1 by performing a genome wide screen in U937 cells. Soon after, Lutejin et al . reported similar findings by conducting a screen in THP-1 cells 2 . While the conclusions of these two studies largely overlap, we arrived at significantly different conclusions regarding how broadly SLC19A1 is used by different cell types. Our study suggests that in addition to SLC19A1, many cultured and primary cell types use alternative, unidentified transporters to import cGAMP and other cyclic dinucleotides (CDNs). This conclusion was based on our findings that inhibition of SLC19A1 did not significantly reduce extracellular cGAMP signaling in multiple cell types, including primary CD14 + peripheral blood mononuclear cells (PBMCs) from most donors. In contrast, Luteijn et al . concluded that SLC19A1 is the major CDN importer in humans, largely based on their use of a radiolabeled [ 32 P] cGAMP uptake assay. Using this assay, they showed that inhibition of SLC19A1 abolishes [ 32 P] uptake in total PBMCs. However, they did not test whether inhibition of SLC19A1 affects extracellular cGAMP signaling in these cells. Here, we highlight an important issue with the [ 32 P] cGAMP uptake assay used by Luteijn et al . and demonstrate that measuring extracellular cGAMP signaling through the STING pathway is currently the best method for evaluating cGAMP import. We also show that inhibition of SLC19A1 has no effect on extracellular cGAMP signaling in total PBMCs, confirming that this cell type relies on other transport mechanisms for cGAMP import.
Open AccessIn response to Luteijn et al .: Concerns regarding cGAMP uptake assay and evidence that SLC19A1 is not the major cGAMP importer in human PBMCs
We previously reported that SLC19A1 is an importer of the immunotransmitter 2’3’-cyclic-GMP-AMP (cGAMP) 1 by performing a genome wide screen in U937 cells. Soon after, Lutejin et al . reported similar findings by conducting a screen in THP-1 cells 2 . While the conclusions of these two studies largely overlap, we arrived at significantly different conclusions regarding how broadly SLC19A1 is used by different cell types. Our study suggests that in addition to SLC19A1, many cultured and primary cell types use alternative, unidentified transporters to import cGAMP and other cyclic dinucleotides (CDNs). This conclusion was based on our findings that inhibition of SLC19A1 did not significantly reduce extracellular cGAMP signaling in multiple cell types, including primary CD14 + peripheral blood mononuclear cells (PBMCs) from most donors. In contrast, Luteijn et al . concluded that SLC19A1 is the major CDN importer in humans, largely based on their use of a radiolabeled [ 32 P] cGAMP uptake assay. Using this assay, they showed that inhibition of SLC19A1 abolishes [ 32 P] uptake in total PBMCs. However, they did not test whether inhibition of SLC19A1 affects extracellular cGAMP signaling in these cells. Here, we highlight an important issue with the [ 32 P] cGAMP uptake assay used by Luteijn et al . and demonstrate that measuring extracellular cGAMP signaling through the STING pathway is currently the best method for evaluating cGAMP import. We also show that inhibition of SLC19A1 has no effect on extracellular cGAMP signaling in total PBMCs, confirming that this cell type relies on other transport mechanisms for cGAMP import.